Your browser doesn't support javascript.
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.
Beltrán-Pavez, Carolina; Riquelme-Barrios, Sebastián; Oyarzún-Arrau, Aarón; Gaete-Argel, Aracelly; González-Stegmaier, Roxana; Cereceda-Solis, Karina; Aguirre, Adam; Travisany, Dante; Palma-Vejares, Ricardo; Barriga, Gonzalo P; Gaggero, Aldo; Martínez-Valdebenito, Constanza; Corre, Nicole Le; Ferrés, Marcela; Balcells, María Elvira; Fernandez, Jorge; Ramírez, Eugenio; Villarroel, Franz; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo.
  • Beltrán-Pavez C; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Riquelme-Barrios S; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Oyarzún-Arrau A; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Gaete-Argel A; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • González-Stegmaier R; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Cereceda-Solis K; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Aguirre A; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Travisany D; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Palma-Vejares R; Translational Medicine Laboratory, Fundación Arturo López Pérez Cancer Center, Santiago, Chile.
  • Barriga GP; Translational Medicine Laboratory, Fundación Arturo López Pérez Cancer Center, Santiago, Chile.
  • Gaggero A; Translational Medicine Laboratory, Fundación Arturo López Pérez Cancer Center, Santiago, Chile.
  • Martínez-Valdebenito C; Centro de Modelamiento Matemático UMI-CNRS 2807, Facultad de Ciencias Físicas y Matemáticas, Universidad de Chile and Fondap Center for Genome Regulation, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
  • Corre NL; INRIA Chile Research Center, Santiago, Chile.
  • Ferrés M; Centro de Modelamiento Matemático UMI-CNRS 2807, Facultad de Ciencias Físicas y Matemáticas, Universidad de Chile and Fondap Center for Genome Regulation, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
  • Balcells ME; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Fernandez J; Laboratory of Emerging Viruses, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Ramírez E; SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Villarroel F; Laboratory of Environmental Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Valiente-Echeverría F; Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Soto-Rifo R; Laboratorio de Infectología y Virología Molecular, Laboratorio de Bioseguridad Nivel 3, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Sci Adv ; 7(7)2021 02.
Article in English | MEDLINE | ID: covidwho-1080728
ABSTRACT
Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, which was used in a 96-well plate format to investigate NAb responses in samples from individuals exposed to SARS-CoV-2 or treated with convalescent plasma. We also identified samples with decreased or enhanced neutralization activity against the D614G spike variant compared with the wild type, indicating the relevance of this variant in host immunity. The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mutation, Missense / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Variants Limits: Animals / Female / Humans / Male Country/Region as subject: South America / Chile Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abe6855

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mutation, Missense / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Variants Limits: Animals / Female / Humans / Male Country/Region as subject: South America / Chile Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abe6855